Compare ANGH & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANGH | ELUT |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United Arab Emirates | United States |
| Employees | 191 | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.6M | 41.9M |
| IPO Year | N/A | 2020 |
| Metric | ANGH | ELUT |
|---|---|---|
| Price | $3.32 | $0.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 31.2K | ★ 60.8K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,293,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.25 | $0.50 |
| 52 Week High | $7.89 | $2.50 |
| Indicator | ANGH | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 48.57 |
| Support Level | $3.21 | $0.87 |
| Resistance Level | $3.91 | $0.99 |
| Average True Range (ATR) | 0.27 | 0.06 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 26.55 | 57.14 |
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. The Group's three reportable segments: Revenue from subscriptions, Revenue from advertisement, and Revenue from live events. It generates the majority of its revenue from subscriptions segment, which is comes from subscription fees. The advertisement revenue segment generated through the sale of advertising across the Group's content. Revenues from live events are generated from the sale of tickets, food and beverage & sponsorship. It derives maximum revenue from KSA.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.